Top Markets
#1 0G 0G +11.60%
#2 Siacoin Siacoin +9.25%
#3 Cash Cat Cash Cat +8.48%
#4 Arbitrum Arbitrum +7.02%
#5 MarsCoin MarsCoin +6.90%
#6 Asteroid Shiba Asteroid Shiba +6.90%
#7 Seeker Seeker +6.12%
#8 Metis Metis +6.04%
#9 Useless Coin Useless Coin +5.01%
#10 Optimism Optimism +4.77%
Coin of the day
0G 0G
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Hisse Senetlerindeki Sıralama #14111
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Hisse Fiyatı
$1.46
Son senkronizasyon: 2026-07-28
Piyasa Değeri
$435.25M
Değişim (1 gün)
-2.34%
Değişim (1 yıl)
-25.65%
Ülke
TW
Ticaret EirGenix Inc. (6589)

Kategori

Healthcare
EirGenix Inc. (6589) için EPS
2026 itibariyle EPS TTM: 0
EirGenix Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
EirGenix Inc. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS
Şirket EPS EPS Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH